Will IPOs Come Back? Investors Watching Anthera; Big Pharma Should Too
This article was originally published in The Pink Sheet Daily
Executive Summary
Anthera's planned offering will be the first real IPO in 18 months and a good indicator of whether there are signs of life in the biotech IPO market.
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009
Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009
Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.
Omeros Debuts With $68 Million IPO Despite Legal Hassles From Former CFO
Seattle biotech Omeros ended its first day of trading Oct. 8 at $8.73, down 13 percent after initially pricing its shares at $10, the low end of its expected range